Carmen Bozic - 26 Jun 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: EVP and CMO
Issuer ticker: VRTX
Reported as of: 26 Jun 2026
Net transaction value: -$287,570
SEC form: 4
Accepted by SEC: 30 Jun 2026, 16:09:42 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Carmen Bozic filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 30 Jun 2026.

Key facts

This page summarizes Carmen Bozic's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Jun 2026, 16:09.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$287,570.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001790029 Primary reporting owner

Bozic Carmen

Relationship: EVP and CMO
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Sale

Transaction value: $287,570
Shares: -596
Change %: -3.7%
Price: $482.50
Shares after: 15,337
Date: 26 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.